Corbus Pharmaceuticals Holdings financials
$6.63−4.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$36.2M | -$24.3M | -$22.0M | -$24.4M | -$19.2M | -$19.8M | -$12.6M | -$15.5M | -$11.0M | -$9.6M | -$10.1M | -$9.5M |
| Net income | -$35.0M | -$23.0M | -$20.6M | -$23.3M | -$17.7M | -$17.0M | -$9.5M | -$13.8M | -$10.0M | -$6.9M | -$8.0M | -$10.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.81 | $-1.23 | $-1.24 | $-1.90 | $-1.44 | $-1.39 | $-0.78 | $-1.15 | $-0.90 | $-0.83 | $-1.81 | $-2.27 |
| EBITDA | -$36.1M | -$24.3M | -$21.9M | -$24.4M | -$19.1M | -$19.7M | -$12.5M | -$15.4M | -$10.8M | -$9.5M | -$10.0M | -$9.3M |
| Operating cash flow | -$29.6M | -$25.6M | -$15.9M | -$15.6M | -$16.6M | -$16.4M | -$10.9M | -$13.9M | -$8.9M | -$8.0M | -$6.0M | -$7.2M |
| Free cash flow | -$29.6M | -$25.6M | -$15.9M | -$15.6M | -$16.6M | -$16.4M | -$10.9M | -$13.9M | -$8.9M | -$8.0M | -$6.0M | -$7.2M |
| Diluted shares | 19.4M | 18.7M | 16.5M | 12.3M | 12.2M | 12.2M | 12.3M | 12.0M | 11.1M | 8.3M | 4.4M | 4.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.4M | $25.7M | $28.5M | $27.0M | $20.0M | $18.9M |
| Short-term investments | $94.6M | $112.6M | $134.8M | $77.0M | $96.5M | $113.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $127.0M | $144.5M | $168.2M | $109.5M | $125.1M | $139.9M |
| Total liabilities | $24.7M | $18.1M | $20.7M | $17.4M | $14.1M | $12.8M |
| Shareholders' equity | $102.2M | $126.3M | $147.5M | $92.1M | $111.0M | $127.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology